Anaplastic Thyroid Carcinoma

An aggressive THYROID GLAND malignancy which generally occurs in IODINE-deficient areas in people with previous thyroid pathology such as GOITER. It is associated with CELL DEDIFFERENTIATION of THYROID CARCINOMA (e.g., FOLLICULAR THYROID CARCINOMA; PAPILLARY THYROID CANCER). Typical initial presentation is a rapidly growing neck mass which upon metastasis is associated with DYSPHAGIA; NECK PAIN; bone pain; DYSPNEA; and NEUROLOGIC DEFICITS.

Also Known As:

Networked: 1408 relevant articles (71 outcomes, 176 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Thyroid Neoplasms (Thyroid Cancer)
3.	medullary Thyroid cancer
4.	Neoplasm Metastasis (Metastasis)
5.	Melanoma (Melanoma, Malignant)

Experts

1.	Antonelli, Alessandro: 20 articles (03/2019 - 07/2008)
2.	Fallahi, Poupak: 18 articles (03/2019 - 07/2008)
3.	Ferrari, Silvia Martina: 17 articles (01/2019 - 07/2008)
4.	Bible, Keith C: 16 articles (03/2022 - 10/2010)
5.	Smallridge, Robert C: 16 articles (01/2020 - 03/2009)
6.	Cabanillas, Maria E: 15 articles (01/2021 - 01/2016)
7.	Iwasaki, Hiroyuki: 14 articles (06/2022 - 08/2017)
8.	Ulisse, Salvatore: 14 articles (03/2022 - 06/2008)
9.	Fusco, Alfredo: 14 articles (01/2020 - 06/2002)
10.	Materazzi, Gabriele: 13 articles (01/2019 - 07/2008)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Anaplastic Thyroid Carcinoma:

1.	lenvatinibIBA 12/22/2020 - "Low-intermediate dose of lenvatinib in anaplastic thyroid cancer is highly effective and safe." 01/01/2017 - "We encountered a case in which lenvatinib was effective for locally advanced anaplastic thyroid carcinoma, leading to an improvement in quality of life and a prolonged life. " 12/01/2018 - "Lenvatinib as a novel treatment for anaplastic thyroid cancer: A retrospective study." 01/01/2021 - "Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview." 01/01/2020 - "Background: Survival rates for anaplastic thyroid cancer (ATC) have not improved in the past four decades; however, preliminary clinical data indicate that lenvatinib may provide efficacy benefits for patients with ATC. "
2.	Paclitaxel (Taxol)FDA LinkGeneric 01/01/2016 - "The Safety and Efficacy of Weekly Paclitaxel Administration for Anaplastic Thyroid Cancer Patients: A Nationwide Prospective Study." 07/28/2021 - "In this study, we created a model of anaplastic thyroid cancer (ATC) cells resistant to paclitaxel and investigated the characteristics of these cells by analyzing the profile of gene expression and comparing it with that of paclitaxel-sensitive original ATC cell lines. " 06/20/2015 - "Concept and design of a nationwide prospective feasibility/efficacy/safety study of weekly paclitaxel for patients with pathologically confirmed anaplastic thyroid cancer (ATCCJ-PTX-P2)." 07/01/2000 - "Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. " 01/01/2023 - "The clinical utilities of paclitaxel in anaplastic thyroid carcinoma (ATC) have been reported. "
3.	dabrafenibIBA 02/14/2023 - "To explore the possibility of a combination of dabrafenib and SHP2 inhibitor in the treatment of anaplastic thyroid carcinoma and to provide a new therapeutic strategy for the treatment of anaplastic thyroid cancer. " 01/01/2023 - "Here we demonstrate the safety and efficacy of laryngotracheal resection and reconstruction after dabrafenib/trametinib for locoregionally advanced BRAF v600e mutated anaplastic thyroid carcinoma." 01/01/2023 - "Patients with B-Raf proto-oncogene (BRAF) v600e mutated anaplastic thyroid carcinoma who receive neoadjuvant dabrafenib/trametinib have improved rates of microscopically margin-negative resection and durable locoregional control. " 01/01/2022 - "Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study." 09/26/2023 - "Complete response of metastatic BRAF V600-mutant anaplastic thyroid cancer following adjuvant dabrafenib and trametinib treatment: A case report."
4.	trametinibIBA 01/01/2023 - "Here we demonstrate the safety and efficacy of laryngotracheal resection and reconstruction after dabrafenib/trametinib for locoregionally advanced BRAF v600e mutated anaplastic thyroid carcinoma." 01/01/2023 - "Patients with B-Raf proto-oncogene (BRAF) v600e mutated anaplastic thyroid carcinoma who receive neoadjuvant dabrafenib/trametinib have improved rates of microscopically margin-negative resection and durable locoregional control. " 01/01/2022 - "Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study." 09/26/2023 - "Complete response of metastatic BRAF V600-mutant anaplastic thyroid cancer following adjuvant dabrafenib and trametinib treatment: A case report." 01/01/2023 - "Case report: Complete response of an anaplastic thyroid carcinoma patient with NRAS Q61R/BRAF D594N mutations to the triplet of dabrafenib, trametinib and PD-1 antibody."
5.	Sunitinib (Sutent)FDA Link 02/01/2012 - "Sunitinib has little or no effect on the growth or differentiation of anaplastic thyroid cancer cells, thus suggesting that it is unlikely to be effective in the treatment of anaplastic thyroid cancer." 09/01/2013 - "Sunitinib showed promising preliminary results against anaplastic thyroid cancer (ATC), and it has been used for some patients who are ineligible for clinical trials. " 01/01/2019 - "Furthermore sunitinib is active in vitro and in vivo against anaplastic thyroid cancer (ATC) cells. " 09/01/2013 - "Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1." 07/01/2013 - "A significant response to sunitinib in a patient with anaplastic thyroid carcinoma."
6.	Docetaxel (Taxotere)FDA Link 09/01/2010 - "High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel." 06/01/2010 - "Docetaxel could be an effective drug for the treatment of anaplastic thyroid cancer, with tolerable toxicity." 06/01/2010 - "A total of seven patients with anaplastic thyroid cancer were enrolled over the course of 30 months and received docetaxel. " 06/01/2010 - "We conducted a prospective feasibility study at a single center to explore the antitumor activity of docetaxel against anaplastic thyroid cancer. " 06/01/2010 - "The feasibility study of docetaxel in patients with anaplastic thyroid cancer."
7.	fosbretabulin (combretastatin A4)IBA 03/01/2009 - "Fosbretabulin is a novel vascular-disrupting agent that has antitumor activity against anaplastic thyroid cancer (ATC) cell lines, xenografts, and demonstrable efficacy in a phase I trial. " 03/01/2009 - "A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome." 10/01/2014 - "Fosbretabulin for the treatment of anaplastic thyroid cancer." 12/01/2012 - "Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer." 08/01/2007 - "Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model."
8.	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 08/01/2020 - "Treatment with a BRAF inhibitor, alone or in combination with a MEK inhibitor, may be considered for BRAF-mutant anaplastic thyroid carcinoma (ATC). " 01/01/2020 - "For BRAF-mutant DTC or anaplastic thyroid cancer (ATC), treatment with inhibitors targeting BRAF and MEK are important advances. " 11/01/2018 - "Recent advances have suggested the combination of BRAF and MEK inhibition may have a profound and durable effect on patients with BRAFV600E-mutated anaplastic thyroid cancer, with a response rate of 69%. " 05/01/2017 - "We document a case in which a patient with anaplastic thyroid carcinoma (ATC) failed to respond to either mTOR/PI3K or combined RAF/MEK inhibition but experienced a dramatic response when both drug regimens were combined.Experimental" 12/01/2016 - "Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells."
9.	sodium-iodide symporter (sodium iodide symporter)IBA 12/01/2017 - "Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma." 09/01/2012 - "Western blotting analysis confirmed that a panel of eight anaplastic thyroid cancer (ATC)-derived cell lines do not express NIS protein, but do express CD46, the MV receptor. " 09/01/2012 - "Anaplastic thyroid cancer is an extremely aggressive disease resistant to radioiodine treatment because of loss of sodium iodide symporter (NIS) expression. " 01/01/2011 - "To evaluate the possibility of a novel Cerenkov luminescence imaging (CLI) for application in thyroid research, we performed feasibility studies of CLI by RI in the thyroid gland and human anaplastic thyroid carcinoma cells expressing sodium iodide symporter gene (ARO-NIS). " 11/01/2004 - "In vitro and in vivo properties of a human anaplastic thyroid carcinoma cell line transfected with the sodium iodide symporter gene."
10.	ErbB Receptors (EGF Receptor)IBA 01/01/2022 - "Nuclear-targeted EGF receptor enhances proliferation and migration of human anaplastic thyroid cancer cells." 01/01/2018 - "CRISPR/Cas9 Genome Editing of Epidermal Growth Factor Receptor Sufficiently Abolished Oncogenicity in Anaplastic Thyroid Cancer." 10/01/2012 - "The epidermal growth factor receptor (EGFR) is overexpressed in the majority of anaplastic thyroid cancers (ATCs). " 08/01/2007 - "The epidermal growth factor receptor (EGFR) has been reported to be overexpressed in anaplastic thyroid carcinoma (ATC). " 08/01/2007 - "Epidermal growth factor receptor status in anaplastic thyroid carcinoma."

Therapies and Procedures

1.	Therapeutics 01/01/2019 - "Anaplastic thyroid cancer patients receiving EBRT to the thyroid area/neck and/or surgical resection had better OS than patients without these therapies, though selection bias likely contributed to improved outcomes since patients who can undergo these therapies tend to have better performance status. " 01/01/2014 - "In anaplastic thyroid cancer, multimodality therapy is superior to surgery alone in achieving local control and possibly survival but the benefit must be weighed against the toxicity. " 01/01/2016 - "Thus, the treatment that is the current standard of care for these patients is largely palliative, and few are cured; however, novel therapies and approaches are being studied in patients with anaplastic thyroid carcinoma and are delineated herein." 01/01/2023 - "Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study." 01/10/2023 - "Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study."
2.	Radiotherapy 07/01/2018 - "Correction to: Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer, by Oweida A, Phan A, Vancourt B, Robin T, Hararah MK, Bhatia S, Milner D, Lennon S, Pike L, Raben D, Haugen B, Pozdeyev N, Schweppe R, and Karam SD. " 01/01/2018 - "Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer." 09/01/2008 - "Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapy." 04/19/2023 - "Prognostic factors in radiotherapy of anaplastic thyroid carcinoma: a single center study over 31 years." 10/09/2020 - "The present study aims to evaluate the outcomes and toxicity of elderly anaplastic thyroid cancer (ATC) patients receiving (chemo)radiotherapy, as well as to identify prognostic factors. "
3.	Drug Therapy (Chemotherapy) 03/01/2022 - "This study aimed to analyze the impact of palliative chemotherapy versus supportive care on overall survival in patients with metastatic anaplastic thyroid carcinoma. " 05/01/2020 - "KLF5 influences cell biological function and chemotherapy sensitivity through the JNK signaling pathway in anaplastic thyroid carcinoma." 01/01/2020 - "Anaplastic thyroid cancer (ATC) is a rare, but nearly uniformly fatal disease that is typically resistant to chemotherapy and radiation. " 01/01/2020 - "BSA-Stabilized Mesoporous Organosilica Nanoparticles Reversed Chemotherapy Resistance of Anaplastic Thyroid Cancer by Increasing Drug Uptake and Reducing Cellular Efflux." 01/01/2020 - "In most cases, anaplastic thyroid carcinomas are diagnosed in later stages of the disease, deeming them inoperable, and showing poor response rates to systemic chemotherapy. "
4.	Photochemotherapy (Photodynamic Therapy) 07/01/2015 - "Here we studied the possibility of using a combination of conventional chemotherapy and photodynamic therapy to inhibit the growth of human anaplastic thyroid cancer in vitro and in vivo. " 01/01/2023 - "For thyroid cancer treatment, nanomaterial-based photothermal therapy or photodynamic therapy, combined with chemotherapy, radiotherapy, or gene therapy, holds promise in reducing invasiveness and prolonging patient survival or alleviating pain in individuals with anaplastic thyroid carcinoma. " 02/01/2018 - "Sulforaphene Enhances The Efficacy of Photodynamic Therapy In Anaplastic Thyroid Cancer Through Ras/RAF/MEK/ERK Pathway Suppression." 12/01/2012 - "Combination with genistein enhances the efficacy of photodynamic therapy against human anaplastic thyroid cancer cells." 12/01/2018 - "Hypericin-assisted photodynamic therapy against anaplastic thyroid cancer."
5.	Photothermal Therapy 01/01/2020 - "In this study, we engineered multifunctional sequential targeting NPs for achieving synergistic antiangiogenic photothermal therapy (PTT) and multimodal imaging-guided diagnosis for anaplastic thyroid carcinoma (ATC) theranostics. " 07/01/2015 - "Single agent nanoparticle for radiotherapy and radio-photothermal therapy in anaplastic thyroid cancer." 01/01/2023 - "For thyroid cancer treatment, nanomaterial-based photothermal therapy or photodynamic therapy, combined with chemotherapy, radiotherapy, or gene therapy, holds promise in reducing invasiveness and prolonging patient survival or alleviating pain in individuals with anaplastic thyroid carcinoma. " 01/01/2022 - "Evaluating the therapeutic efficacy of radiolabeled BSA@CuS nanoparticle-induced radio-photothermal therapy against anaplastic thyroid cancer." 01/01/2022 - "Radionuclide 131I-labeled albumin-indocyanine green nanoparticles for synergistic combined radio-photothermal therapy of anaplastic thyroid cancer."